These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32561477)

  • 1. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
    Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
    Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRP78 blockade overcomes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer.
    Park J; Purushothaman B; Hong S; Choi M; Jegal KH; Park M; Song JM; Kang KW
    Life Sci; 2024 Jul; 348():122681. PubMed ID: 38697281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
    Chen MC; Chen CH; Wang JC; Tsai AC; Liou JP; Pan SL; Teng CM
    Cell Death Dis; 2013 Sep; 4(9):e810. PubMed ID: 24052078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
    Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A
    Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
    Peled N; Wynes MW; Ikeda N; Ohira T; Yoshida K; Qian J; Ilouze M; Brenner R; Kato Y; Mascaux C; Hirsch FR
    Cell Oncol (Dordr); 2013 Jul; 36(4):277-88. PubMed ID: 23619944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
    Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
    Kook E; Lee J; Kim DH
    Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
    Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
    Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
    Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
    Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.
    Nilsson MB; Sun H; Diao L; Tong P; Liu D; Li L; Fan Y; Poteete A; Lim SO; Howells K; Haddad V; Gomez D; Tran H; Pena GA; Sequist LV; Yang JC; Wang J; Kim ES; Herbst R; Lee JJ; Hong WK; Wistuba I; Hung MC; Sood AK; Heymach JV
    Sci Transl Med; 2017 Nov; 9(415):. PubMed ID: 29118262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.
    Liu Z; Gao W
    Toxicol Appl Pharmacol; 2017 Nov; 335():16-27. PubMed ID: 28942004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
    Tohmé R; Izadmehr S; Gandhe S; Tabaro G; Vallabhaneni S; Thomas A; Vasireddi N; Dhawan NS; Ma'ayan A; Sharma N; Galsky MD; Ohlmeyer M; Sangodkar J; Narla G
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
    Garofalo M; Romano G; Di Leva G; Nuovo G; Jeon YJ; Ngankeu A; Sun J; Lovat F; Alder H; Condorelli G; Engelman JA; Ono M; Rho JK; Cascione L; Volinia S; Nephew KP; Croce CM
    Nat Med; 2011 Dec; 18(1):74-82. PubMed ID: 22157681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
    Zhao L; Wang Y; Sun X; Zhang X; Simone N; He J
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Methionine accentuates anti-tumor action of Gefitinib in Gefitinib-resistant lung adenocarcinoma: Role of EGFR/ERK/AKT signaling and histone H3K36me2 alteration.
    Pal S; Kabeer SW; Tikoo K
    Toxicol Appl Pharmacol; 2024 Apr; 485():116907. PubMed ID: 38521369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.
    Lopez Sambrooks C; Baro M; Quijano A; Narayan A; Cui W; Greninger P; Egan R; Patel A; Benes CH; Saltzman WM; Contessa JN
    Cancer Res; 2018 Sep; 78(17):5094-5106. PubMed ID: 30026325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.